Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models
PUBT · 2d ago
Share
Listen to the news
- Actuate Therapeutics disclosed new preclinical studies in pancreatic cancer combining elraglusib with RAS inhibitors zoldonrasib or daraxonrasib.
- Work showed stronger anti-tumor effects for the combinations than either drug alone across multiple murine and human models.
- Separate tests in chemotherapy-resistant models also indicated improved activity for elraglusib with zoldonrasib versus single-agent treatment.
- Additional study results will be presented at upcoming medical conferences.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823452) on September 09, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending